Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia

Summary. Elevated mammalian target of rapamycin (mTOR) signaling has been reported to correlate with poor prognosis in acute lymphoblastic leukemia (ALL) patients. Rapamycin, an mTOR kinase inhibitor, and also a potent autophagy inducer, could not only effectively reverse glucocorticoid resistance,...

Full description

Saved in:
Bibliographic Details
Date:2023
Main Authors: Gong, Y., Wu, J., Yang, R., Zhang, L., Ma, Z.
Format: Article
Language:English
Published: PH Akademperiodyka 2023
Subjects:
Online Access:https://exp-oncology.com.ua/index.php/Exp/article/view/2020-1-3
Tags: Add Tag
No Tags, Be the first to tag this record!
Journal Title:Experimental Oncology

Institution

Experimental Oncology
id oai:ojs2.ex.aqua-time.com.ua:article-199
record_format ojs
institution Experimental Oncology
baseUrl_str
datestamp_date 2023-10-11T16:42:32Z
collection OJS
language English
topic acute lymphoblastic leukemia
autophagy
ciclopirox olamine
ferritin
rapamycin
spellingShingle acute lymphoblastic leukemia
autophagy
ciclopirox olamine
ferritin
rapamycin
Gong, Y.
Wu, J.
Yang, R.
Zhang, L.
Ma, Z.
Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia
topic_facet acute lymphoblastic leukemia
autophagy
ciclopirox olamine
ferritin
rapamycin
acute lymphoblastic leukemia
autophagy
ciclopirox olamine
ferritin
rapamycin
format Article
author Gong, Y.
Wu, J.
Yang, R.
Zhang, L.
Ma, Z.
author_facet Gong, Y.
Wu, J.
Yang, R.
Zhang, L.
Ma, Z.
author_sort Gong, Y.
title Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia
title_short Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia
title_full Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia
title_fullStr Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia
title_full_unstemmed Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia
title_sort rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia
title_alt Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia
description Summary. Elevated mammalian target of rapamycin (mTOR) signaling has been reported to correlate with poor prognosis in acute lymphoblastic leukemia (ALL) patients. Rapamycin, an mTOR kinase inhibitor, and also a potent autophagy inducer, could not only effectively reverse glucocorticoid resistance, but also promote autophagy in the ALL cells. Autophagy has been suggested to play a paradoxical role in cancer treatment. The aim of this study was to address the role of the rapamycin-induced autophagy in the leukemia treatment. Materials and Methods: Cell proliferation was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay in ALL cell lines of CEM-C1 and CEM-C7. Western Blot analysis was performed to test protein expressions. Results: Inhibition of mTOR by rapamycin could reverse glucocorticoid resistance in CEM-C1 cells, and also induce autophagy in these cells by up-regulation of LC3-II and Beclin-1 expressions. This autophagy played a pro-survival role since its inhibition by 6-amino-3-methylpurine or chroloquine could enhance rapamycin-induced cell death. Rapamycin increased the expression of intracellular ferritin, and this effect could be totally blocked by 6-amino-3-methylpurine and chroloquine, suggesting that the protective role of autophagy might be mediated through up-regulation of ferritin, the major iron-binding stress protein. Ciclopirox olamine, an iron chelator, could enhance rapamycin’s anti-leukemia effect by down-regulation of intracellular ferritin expression. Conclusions: All these findings would suggest that rapamycin-induced autophagy plays a pro-survival role in leukemia cells and this effect might be mediated by up-regulation of intracellular ferritin expression. We hypothesize that the combination of mTOR pathway inhibitors and autophagy inhibition is rational and would induce strong anti-leukemia effects in ALL.
publisher PH Akademperiodyka
publishDate 2023
url https://exp-oncology.com.ua/index.php/Exp/article/view/2020-1-3
work_keys_str_mv AT gongy rapamycininducedautophagyplaysaprosurvivalrolebyenhancingupregulationofintracellularferritinexpressioninacutelymphoblasticleukemia
AT wuj rapamycininducedautophagyplaysaprosurvivalrolebyenhancingupregulationofintracellularferritinexpressioninacutelymphoblasticleukemia
AT yangr rapamycininducedautophagyplaysaprosurvivalrolebyenhancingupregulationofintracellularferritinexpressioninacutelymphoblasticleukemia
AT zhangl rapamycininducedautophagyplaysaprosurvivalrolebyenhancingupregulationofintracellularferritinexpressioninacutelymphoblasticleukemia
AT maz rapamycininducedautophagyplaysaprosurvivalrolebyenhancingupregulationofintracellularferritinexpressioninacutelymphoblasticleukemia
first_indexed 2025-07-17T12:16:26Z
last_indexed 2025-07-17T12:16:26Z
_version_ 1850411144300199936
spelling oai:ojs2.ex.aqua-time.com.ua:article-1992023-10-11T16:42:32Z Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia Gong, Y. Wu, J. Yang, R. Zhang, L. Ma, Z. acute lymphoblastic leukemia, autophagy, ciclopirox olamine, ferritin, rapamycin acute lymphoblastic leukemia, autophagy, ciclopirox olamine, ferritin, rapamycin Summary. Elevated mammalian target of rapamycin (mTOR) signaling has been reported to correlate with poor prognosis in acute lymphoblastic leukemia (ALL) patients. Rapamycin, an mTOR kinase inhibitor, and also a potent autophagy inducer, could not only effectively reverse glucocorticoid resistance, but also promote autophagy in the ALL cells. Autophagy has been suggested to play a paradoxical role in cancer treatment. The aim of this study was to address the role of the rapamycin-induced autophagy in the leukemia treatment. Materials and Methods: Cell proliferation was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay in ALL cell lines of CEM-C1 and CEM-C7. Western Blot analysis was performed to test protein expressions. Results: Inhibition of mTOR by rapamycin could reverse glucocorticoid resistance in CEM-C1 cells, and also induce autophagy in these cells by up-regulation of LC3-II and Beclin-1 expressions. This autophagy played a pro-survival role since its inhibition by 6-amino-3-methylpurine or chroloquine could enhance rapamycin-induced cell death. Rapamycin increased the expression of intracellular ferritin, and this effect could be totally blocked by 6-amino-3-methylpurine and chroloquine, suggesting that the protective role of autophagy might be mediated through up-regulation of ferritin, the major iron-binding stress protein. Ciclopirox olamine, an iron chelator, could enhance rapamycin’s anti-leukemia effect by down-regulation of intracellular ferritin expression. Conclusions: All these findings would suggest that rapamycin-induced autophagy plays a pro-survival role in leukemia cells and this effect might be mediated by up-regulation of intracellular ferritin expression. We hypothesize that the combination of mTOR pathway inhibitors and autophagy inhibition is rational and would induce strong anti-leukemia effects in ALL. Summary. Elevated mammalian target of rapamycin (mTOR) signaling has been reported to correlate with poor prognosis in acute lymphoblastic leukemia (ALL) patients. Rapamycin, an mTOR kinase inhibitor, and also a potent autophagy inducer, could not only effectively reverse glucocorticoid resistance, but also promote autophagy in the ALL cells. Autophagy has been suggested to play a paradoxical role in cancer treatment. The aim of this study was to address the role of the rapamycin-induced autophagy in the leukemia treatment. Materials and Methods: Cell proliferation was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay in ALL cell lines of CEM-C1 and CEM-C7. Western Blot analysis was performed to test protein expressions. Results: Inhibition of mTOR by rapamycin could reverse glucocorticoid resistance in CEM-C1 cells, and also induce autophagy in these cells by up-regulation of LC3-II and Beclin-1 expressions. This autophagy played a pro-survival role since its inhibition by 6-amino-3-methylpurine or chroloquine could enhance rapamycin-induced cell death. Rapamycin increased the expression of intracellular ferritin, and this effect could be totally blocked by 6-amino-3-methylpurine and chroloquine, suggesting that the protective role of autophagy might be mediated through up-regulation of ferritin, the major iron-binding stress protein. Ciclopirox olamine, an iron chelator, could enhance rapamycin’s anti-leukemia effect by down-regulation of intracellular ferritin expression. Conclusions: All these findings would suggest that rapamycin-induced autophagy plays a pro-survival role in leukemia cells and this effect might be mediated by up-regulation of intracellular ferritin expression. We hypothesize that the combination of mTOR pathway inhibitors and autophagy inhibition is rational and would induce strong anti-leukemia effects in ALL. PH Akademperiodyka 2023-06-01 Article Article application/pdf https://exp-oncology.com.ua/index.php/Exp/article/view/2020-1-3 10.32471/exp-oncology.2312-8852.vol-42-no-1.14067 Experimental Oncology; Vol. 42 No. 1 (2020): Experimental Oncology; 11-15 Експериментальна онкологія; Том 42 № 1 (2020): Експериментальна онкологія; 11-15 2312-8852 1812-9269 10.32471/exp-oncology.2312-8852.vol-42-no-1 en https://exp-oncology.com.ua/index.php/Exp/article/view/2020-1-3/2020-1-3 Copyright (c) 2023 Experimental Oncology https://creativecommons.org/licenses/by-nc/4.0/